Prolotherapy: An efficient remedy for Tietze syndrome.
J Again Musculoskelet Rehabil. 2017 Sep 22;30(5):975-978
Authors: Senturk E, Sahin E, Serter S
PURPOSE: To match the short-term impact of prolotherapy and conservative terapy for the Tietze syndrome.
PATIENTS AND METHODS: From 2013 to 2014, twenty-one sufferers underwent prolotherapy (group 1) and 13 underwent conservative remedy with analgesics (group 2). A visible analogue rating (VAS) was recorded for measurement of ache depth in all sufferers earlier than (Pre VAS) and after injection first day (VAS1), first week (VAS2) and fourth week (VAS3). Group 2 had been obtained systemic nonsteroidal anti-inflammatory drug. VAS rating was recorded equally on the similar occasions (Pre VAS, VAS1, VAS2, VAS3), and medical impacts had been in contrast between the 2 teams.
RESULTS: The imply VAS rating (mm) earlier than prolotherapy was 7.10 in sufferers who obtained prolotherapy, and seven.14 mm in sufferers who handled nonsteroidal anti-inflammatory drug. The imply VAS after the fist injection was 2.19 mm and dropped to 1.52 mm after the third injection. The imply VAS after the nonsteroidal anti-inflammatory drug therapy dropped 2.62 mm and through the identical scores to three weeks later. There was no vital distinction between the group 1 and group 2 within the age, intercourse and comorbidity. Additionally there was no vital distinction between the group 1 and group 2 in medical and radiological proof. The prolotherapy group confirmed a quicker restoration, together with considerably diminished clinic findings (p: zero.001). Third VAS is important discovering for the prolotherapy group.
CONCLUSION: Prolotherapy might be carried out safely and is a technique with a good long run therapies for Tietze Syndrome. It might be the best process for sufferers with medication negative effects and advers occasions particularly for these with restricted liver and kidney reserve or vital comorbidities.
PMID: 28505950 [PubMed – indexed for MEDLINE]